All In Biotech

Drug Trial Radar · NCT05033080

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 435 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

435

Actual

Start

Sep 14, 2021

Primary completion

May 12, 2023

Study completion Nov 21, 2023

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Sep 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).

Conditions

  • Cystic Fibrosis

Interventions

  • VX-121/TEZ/D-IVADrug

    Fixed-dose combination tablets for oral administration.

  • ELX/TEZ/IVADrug

    Fixed-dose combination tablets for oral administration.

  • IVADrug

    Tablet for oral administration.

  • Placebo (matched to VX-121/TEZ/D-IVA)Drug

    Placebo matched to VX-121/TEZ/D-IVA for oral administration.

  • Placebo (matched to ELX/TEZ/IVA)Drug

    Placebo matched to ELX/TEZ/IVA for oral administration.

  • Placebo (matched to IVA)Drug

    Placebo matched to IVA for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)Time frame: From Baseline Through Week 24

Locations

139 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner University of Arizona Medical Center

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Miller Children's Hospital / Long Beach Memorial

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Kaiser Permanente

    Oakland, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California San Francisco, Lung Transplant Program

    San Francisco, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • University of Florida, Shands Hospital

    Gainesville, Florida

  • Joe DiMaggio Cystic Fibrosis & Pulmonary Center

    Hollywood, Florida

  • Central Florida Pulmonary Group, PA

    Orlando, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Johns Hopkins All Children's Hospital Outpatient Care Center

    St. Petersburg, Florida

  • The Emory Clinic at Chantilly

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • St. Luke's Cystic Fibrosis Center of Idaho

    Boise, Idaho

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Kosair Charities Pediatric Clinical Research Unit

    Louisville, Kentucky

  • Tulane Medical Center

    New Orleans, Louisiana

  • Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Michigan Medicine

    Ann Arbor, Michigan

  • Helen DeVos Children's Hospital CF Center

    Grand Rapids, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Childrens Hospital University of Missouri Health Sciences Center

    Columbia, Missouri

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Cardinal Glennon Children's Hospital - St. Louis University

    St Louis, Missouri

  • Washington University School of Medicine / St. Louis Children's Hospital

    St Louis, Missouri

  • Billings Clinic

    Billings, Montana

  • Nebraska Medical Center

    Omaha, Nebraska

  • Dartmouth Hitchcock, Manchester

    Manchester, New Hampshire

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.